Search

everythinglearnresearchcommunity

for

Search:↓

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.

Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Apremilast did not work for treating severe alopecia areata.

A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.

Abrocitinib may effectively treat stubborn alopecia universalis.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Baricitinib significantly improves hair regrowth in severe alopecia areata.

Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

Upadacitinib effectively treats pyoderma gangrenosum.

Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Baricitinib is a promising treatment for alopecia areata.

CTP-543 is generally safe for treating alopecia areata.

Baricitinib helps with severe hair loss, negative-pressure therapy lowers hernia recurrence, tranexamic acid reduces bleeding, robot-assisted breast surgery may improve outcomes, and acellular dermal matrix could decrease breast reconstruction complications.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.